Page last updated: 2024-09-05

sb 203580 and atenolol

sb 203580 has been researched along with atenolol in 2 studies

Compound Research Comparison

Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)	Studies (atenolol)	Trials (atenolol)	Recent Studies (post-2010) (atenolol)
3,489	4	1,137	5,473	1,950	852

Protein Interaction Comparison

Protein	Taxonomy	atenolol (IC50)
Beta-1 adrenergic receptor	Homo sapiens (human)	0.7468
Alpha-1D adrenergic receptor	Homo sapiens (human)	0.23
Alpha-1A adrenergic receptor	Homo sapiens (human)	0.23
Alpha-1B adrenergic receptor	Homo sapiens (human)	0.23

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Albrecht, W; Bauer, SM; Laufer, SA; Unger, A	1
Goshima, H; Ishizuka, T; Ozawa, A; Watanabe, Y	1

Other Studies

2 other study(ies) available for sb 203580 and atenolol

Article	Year
Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases. Journal of medicinal chemistry, 2017, 07-13, Volume: 60, Issue:13 Topics: Aminopyridines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Discovery; Humans; Imidazoles; Inflammation; Mitogen-Activated Protein Kinase 14; Phosphodiesterase 4 Inhibitors; Protein Kinase Inhibitors; Tumor Necrosis Factor-alpha	2017
Involvement of β-adrenoceptors in the differentiation of human induced pluripotent stem cells into mesodermal progenitor cells. European journal of pharmacology, 2014, Oct-05, Volume: 740 Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Agonists; Atenolol; Cell Differentiation; Cell Line; Cyclic AMP-Dependent Protein Kinases; Humans; Imidazoles; Induced Pluripotent Stem Cells; Isoproterenol; Isoquinolines; p38 Mitogen-Activated Protein Kinases; Propanolamines; Protein Kinase Inhibitors; Pyridines; Receptors, Adrenergic, beta; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2	2014

Article

Year

Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases.

Journal of medicinal chemistry, 2017, 07-13, Volume: 60, Issue:13

Topics: Aminopyridines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Discovery; Humans; Imidazoles; Inflammation; Mitogen-Activated Protein Kinase 14; Phosphodiesterase 4 Inhibitors; Protein Kinase Inhibitors; Tumor Necrosis Factor-alpha

2017

Involvement of β-adrenoceptors in the differentiation of human induced pluripotent stem cells into mesodermal progenitor cells.

European journal of pharmacology, 2014, Oct-05, Volume: 740

Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Agonists; Atenolol; Cell Differentiation; Cell Line; Cyclic AMP-Dependent Protein Kinases; Humans; Imidazoles; Induced Pluripotent Stem Cells; Isoproterenol; Isoquinolines; p38 Mitogen-Activated Protein Kinases; Propanolamines; Protein Kinase Inhibitors; Pyridines; Receptors, Adrenergic, beta; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2

2014